Prescient Therapeutics

Prescient Therapeutics FCF Margin

The Free Cash Flow Margin of Prescient Therapeutics (PTX.AX) as of Nov 22, 2026 is -166.27 %. In the previous year, Free Cash Flow Margin was -199.30 % — a change of -16.57% (higher).

FCF Margin

-166.27 %

YoY

-16.57%

Last updated:

Free Cash Flow Margin of Prescient Therapeutics is 2025 -166.27 % . Free Cash Flow Margin of Prescient Therapeutics was 2024 -199.30 % . It decreases by -16.57% higher compared to the previous year.

The Prescient Therapeutics FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-228.85 AUD
Jan 1, 2019
-5,821.36 AUD
Jan 1, 2020
-225.41 AUD
Jan 1, 2021
-335.22 AUD
Jan 1, 2022
-228.54 AUD
Jan 1, 2023
-254.98 AUD
Jan 1, 2024
-199.30 AUD
Jan 1, 2025
-166.27 AUD
The Prescient Therapeutics FCF Margin history
YEARFCF MarginYoY
-166.27 %-16.57%
-199.30 %-21.84%
-254.98 %+11.57%
-228.54 %-31.82%
-335.22 %+48.71%
-225.41 %-96.13%
-5,821.36 %+2,443.77%
-228.85 %-88.40%
-1,973.24 %-86.46%
-14,576.18 %+110.66%
-6,919.35 %-55.70%
-15,618.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prescient Therapeutics Stock analysis

What does Prescient Therapeutics do? Prescient Therapeutics Ltd is an Australian biotechnology company focused on developing novel cancer therapies. The company was founded in 2006. Its business model is based on leveraging modern technologies and research findings to develop innovative solutions for cancer treatment. Prescient Therapeutics operates in two segments: drug development and research services. The company collaborates closely with leading scientists and medical institutions to utilize the latest advancements in cancer research and bring new drugs to the market. One of its products, PTX-200, is a novel inhibitor of protein kinase CK2 that has shown efficacy in clinical studies against various types of cancer. Another important product is OmniCAR, a next-generation CAR-T cell therapy that allows for selective recognition and destruction of cancer cells. Prescient Therapeutics aims to solidify its position as a leading provider of innovative cancer treatments through a rigorous validation strategy and collaboration with doctors and patients. The company has made significant progress in the development of new cancer therapies, holding numerous patents and establishing partnerships with leading medical institutions. Its goal is to meet the unmet needs of cancer patients and create a better future for cancer therapy. Prescient Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prescient Therapeutics stock

Free Cash Flow Margin of Prescient Therapeutics is -166.27 % in 2025.

Free Cash Flow Margin of Prescient Therapeutics changed from -199.30 % to -166.27 %, representing a -16.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Prescient Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Prescient Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Prescient Therapeutics

All Key Metrics — Prescient Therapeutics